NASDAQ · CMMB
Chemomab Therapeutics Ltd. American Depositary Share
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CMMB: Nov 5, 2026
Chemomab Therapeutics Ltd. American Depositary Share is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-1.4.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks- RTTNews · Aug 19, 11:05 AM EDTChemomab Loss Widens In Q2; Eyes Phase 2 Data For Nebokitug In H1 2028(RTTNews) – Chemomab Therapeutics Ltd. (CMMB), a clinical-stage biotech company, on Wednesday released financial results for the second quarter ended June 30, 2026.
- RTTNews · Jul 10, 12:10 PM EDTWeekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal(RTTNews) – This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech and pharmaceutical sectors.
- RTTNews · Jul 8, 8:17 AM EDTChemomab Therapeutics, Scipher Medicine Announce Merger Agreement, Stock Down In Pre-Market(RTTNews) – Wednesday, Chemomab Therapeutics Ltd. (CMMB) and Scipher Medicine Corporation announced a merger agreement to combine the companies, which will focus on advancing nebokitug, a first-in-class clinical stage anti-CCL24 antibody, into a Phase 2 trial for the treatment of
- RTTNews · Jul 3, 1:15 AM EDTTop Biotech Gainers: PPCB Launches Share Buyback, VRXA Partners With ATUM, SLS On Watch(RTTNews) – Today's top gainers include SL Science, which was recently listed on the Nasdaq; Chemomab, gearing up for a Phase 3 trial in primary sclerosing cholangitis; Propanc, following the launch of a share repurchase program; and Tectonic, drawing investor attention ahead of
- RTTNews · May 26, 3:50 AM EDTTop Biotech Gainers: AKTX Rallies; GOVX Up On Ebola Concerns; SLGL Awaits Catalysts; CMMB On Watch(RTTNews) – Biotech stocks witnessed strong momentum on Friday, with Akari Therapeutics leading the pack, driven by encouraging preclinical pancreatic cancer data for AKTX-101. MetaVia, GeoVax, Polyrizon, and Sol-Gel were also some of the companies that captured Wall Street's at
- RTTNews · Dec 14, 9:51 PM ESTMarket Pulse: Tilray Leads After-Hours Rally As Biotech Peers Surge(RTTNews) – A quiet news day didn't stop several high-volatility healthcare and cannabis stocks from posting sharp after-hours gains on Friday, with traders leaning into recent catalysts and technical momentum.
- Zacks · Oct 23, 10:27 AM EDTALKS to Enter Sleep Disorder Market With $2.1B Avadel AcquisitionAlkermes inks $2.1B deal to acquire Avadel, adding the latter's Lumryz and new growth potential to its portfolio.
- Zacks · Oct 23, 10:00 AM EDTBest Momentum Stocks to Buy for Oct. 23PARR, CMMB and GES made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 23, 2025.
- Zacks · Oct 23, 7:05 AM EDTNew Strong Buy Stocks for Oct. 23: MQ, GES and MoreMQ, GES, TRV, CMMB and PARR have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 23, 2025.
- RTTNews · Oct 23, 12:45 AM EDTVTYX, MEDP, INBX Jump After Hours On Key Updates(RTTNews) – Biotech stocks surged in after-hours trading on Wednesday, October 22, led by Ventyx Biosciences, which soared over 88% on positive Phase 2 data. A mix of earnings updates, clinical news, and investor interest lifted several names across the sector, including Medpace,
- Zacks · Oct 22, 10:18 AM EDTSNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease StudySanofi's efdoralprin alfa meets all key endpoints in a global phase II study, showing potential as a first restorative recombinant therapy for AATD.
- Zacks · Oct 21, 9:34 AM EDTRoche's Gazyva Secures FDA Nod for Label Expansion in Lupus NephritisRHHBY secures FDA approval to expand Gazyva's label for treating lupus nephritis, offering patients a faster and more convenient treatment option.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Chemomab Therapeutics Ltd. American Depositary Share from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.